Seminars in Radiation Oncology
Volume 20, Issue 4 , Pages 267-273.e3, October 2010

Enhancing Radiotherapy Through a Greater Understanding of Homologous Recombination

Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY

Radiotherapy for the treatment of cancer can cause a wide range of cellular effects, the most biologically potent of which is the double-strand break in DNA. The process of repairing DNA double-strand breaks involves 1 of 2 major mechanisms: nonhomologous end joining or homologous recombination. In this review, we review the molecular mechanisms of homologous recombination, in particular as it relates to the repair of DNA damage from ionizing radiation. We also present specific situations in which homologous recombination may be dysfunctional in human cancers and how this functional abnormality can be recognized. We also discuss the therapeutic opportunities that can be exploited based on deficiencies in homologous recombination at various steps in the DNA repair pathway. Side-by-side with these potential therapeutic opportunities, we review the contemporary clinical trials in which strategies to exploit these defects in homologous recombination can be enhanced by the use of radiotherapy in conjunction with biologically targeted agents. We conclude that the field of radiation oncology has only scratched the surface of a potentially highly efficacious therapeutic strategy.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported in part by the ASTRO Resident in Radiation Oncology Research Seed Grant (CAB) and the National Cancer Institute and the Susan G. Komen Breast Cancer Research Foundation (SNP).

PII: S1053-4296(10)00035-4

doi:10.1016/j.semradonc.2010.05.001

Seminars in Radiation Oncology
Volume 20, Issue 4 , Pages 267-273.e3, October 2010